Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
exemestane + ruxolitinib
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of exemestane, an aromatase inhibitor, and ruxolitinib, a JAK1/JAK2 inhibitor. Exemestane works by irreversibly binding to the active site of the aromatase enzyme, resulting in permanent inhibition of estrogen production, while ruxolitinib inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2, which mediate signaling of cytokines and growth factors important for hematopoiesis and immune function. This combination is being investigated for the treatment of estrogen receptor-positive breast cancer.
02
Targets
Beyond the preview
Go deeper on exemestane + ruxolitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on exemestane + ruxolitinib.